-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
ATV006
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2647441-36-7.gif)
| Category | SARS-CoV |
| CAS | 2647441-36-7 |
| Description | ATV006 is a potent, orally active antiviral agent and ester prodrugs of GS-441524. ATV006 inhibits the replication of SARS-CoV-2 and its variants. |
Product Information
| Synonyms | ATV006|2647441-36-7|Obeldesivir|D-Altrononitrile, 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-, 6-(2-methylpropanoate)|D-Altrononitrile, 2-C-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-, 6-(2-methylpropanoate)|Obeldesivir [INN]|UNII-Q55KCM7PXB|Q55KCM7PXB|CHEMBL4863829|EX-A6600|HY-145994|CS-0498195|2-C-(4-Aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-d -altrononitrile 6-(2-methylpropanoate) |
| Molecular Weight | 361.35 |
| Molecular Formula | C16H19N5O5 |
| Canonical SMILES | CC(C)C(=O)OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O |
| Purity | 99.41% |
| Solubility | In Vitro: DMSO : 250 mg/mL(691.85 mM;Need ultrasonic) |
| Appearance | White to off-white (Solid) |
| Storage | 4°C, protect from light * In solvent : -80°C, 6 months -20°C, 1 month (protect from light) |
| Complexity | 595 |
| Exact Mass | 361.13861872 |
| In Vitro | ATV006 (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern ATV006 has an overall >4-fold and >12-fold potency improvement in inhibiting the replication of Delta and Omicron variants, with EC50 values of 0.349 μM and 0.106 μM, respectively MCE has not independently confirmed the accuracy of these methods. They are for reference only In Vivo ATV006 (5-25 mg/kg; p.o. and i.v.; Sprague Dawley rats) has favorable pharmacokinetic profiles in rats with high oral bioavailability (F %) of 81.5% and maximum blood concentration (Cmax) of 8.2 μM. |
| In Vivo | ATV006 (0.001-100 μM; 48 h; Vero E6 cells) inhibits the replication of authentic SARS-CoV-2 and its variants of concern. |
| Target | SARS-CoV |
| XLogP3-AA | -0.3 |
